Seeking Alpha

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating ...
Nasdaq

Marker Therapeutics Reports Promising Results from Phase 1 APOLLO Study of MT-601 in Relapsed Lymphoma Patients

Marker Therapeutics, Inc. provided an update on its Phase 1 APOLLO study of MT-601, a novel T cell therapy targeting relapsed lymphoma patients. The study reported an objective response rate of 78% ...
Seeking Alpha

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma

HOUSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (MRKR) (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies ...